DCBY02 represents a highly specialized humanized monoclonal antibody specifically engineered to target the human CD93 (C1qR1) receptor with exceptional binding affinity. It effectively facilitates the measurable normalization of tumor vasculature by blocking the interaction between CD93 and its ligands, such as IGFBP7 and MMRN2, across various preclinical experimental models to evaluate the reduction of intratumoral hypoxia and the enhancement of T-cell infiltration during strictly monitored laboratory observation periods and functional immuno-normalization assays to ensure high experimental sensitivity.

Human

Monoclonal

Unconjugated